Replies to post #243107 on Biotech Values

[DewDiligence]

AMTI—(-58%)—fails another phase-2 in UC:

https://finance.yahoo.com/news/applied-molecular-transport-announces-top-223000851.html

Similar clinical remission rates observed in patients receiving AMT-101 monotherapy compared to placebo at week 12

The prior phase-2 failure was in a trial testing AMT-101 as an addend to Humira (#msg-169325900). The failure reported today was in a trial testing AMT-101 vs placebo. Moral: AMT-101 does not have activity against UC.